150 related articles for article (PubMed ID: 36353660)
1. Low Blood Levels of LRG1 Before Radical Prostatectomy Identify Patients with High Risk of Progression to Castration-resistant Prostate Cancer.
Guldvik IJ; Braadland PR; Sivanesan S; Ramberg H; Kristensen G; Tennstedt P; Røder A; Schlomm T; Berge V; Eri LM; Lilleby W; Mills IG; Taskén KA
Eur Urol Open Sci; 2022 Nov; 45():68-75. PubMed ID: 36353660
[TBL] [Abstract][Full Text] [Related]
2. Alterations of plasma exosomal proteins and motabolies are associated with the progression of castration-resistant prostate cancer.
Liu P; Wang W; Wang F; Fan J; Guo J; Wu T; Lu D; Zhou Q; Liu Z; Wang Y; Shang Z; Chan FL; Yang W; Li X; Zhao SC; Zheng Q; Wang F; Wu D
J Transl Med; 2023 Jan; 21(1):40. PubMed ID: 36681849
[TBL] [Abstract][Full Text] [Related]
3. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort.
Cooperberg MR; Davicioni E; Crisan A; Jenkins RB; Ghadessi M; Karnes RJ
Eur Urol; 2015 Feb; 67(2):326-33. PubMed ID: 24998118
[TBL] [Abstract][Full Text] [Related]
4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
5. Circulating Vitamin D and Selenium Levels and Outcome in Prostate Cancer Patients: Lessons from the MARTINI-Lifestyle Cohort.
Thederan I; Chandrasekar T; Tennstedt P; Knipper S; Kuehl L; Tilki D; Augustin M; Heinzer H; Zyriax BC
Eur Urol Focus; 2021 Sep; 7(5):973-979. PubMed ID: 33408047
[TBL] [Abstract][Full Text] [Related]
6. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis.
Kristensen G; Berg KD; Toft BG; Stroomberg HV; Nolley R; Brooks JD; Brasso K; Roder MA
J Clin Pathol; 2019 Oct; 72(10):696-704. PubMed ID: 31331953
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of the prognostic nutritional index for the prognosis of Chinese patients with high/extremely high-risk prostate cancer after radical prostatectomy.
Yang F; Pan M; Nie J; Xiao F; Zhang Y
World J Clin Cases; 2022 Sep; 10(25):8863-8871. PubMed ID: 36157668
[TBL] [Abstract][Full Text] [Related]
9. Role of Metabolic Syndrome on Perioperative and Oncological Outcomes at Radical Prostatectomy in a Low-risk Prostate Cancer Cohort Potentially Eligible for Active Surveillance.
Colicchia M; Morlacco A; Rangel LJ; Carlson RE; Dal Moro F; Karnes RJ
Eur Urol Focus; 2019 May; 5(3):425-432. PubMed ID: 29306730
[TBL] [Abstract][Full Text] [Related]
10. The prognostic and predictive value of TMPRSS2-ERG gene fusion and ERG protein expression in prostate cancer biopsies.
Berg KD
Dan Med J; 2016 Dec; 63(12):. PubMed ID: 27910803
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of combined analysis of pro-NPY and ERG in localized prostate cancer.
Kristensen G; Røder MA; Berg KD; Elversang J; Iglesias-Gato D; Moreira J; Toft BG; Brasso K
APMIS; 2018 Oct; 126(10):804-813. PubMed ID: 30191621
[TBL] [Abstract][Full Text] [Related]
12. Enumeration and Changes in Circulating Tumor Cells and Their Prognostic Value in Patients Undergoing Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer-Translational Research Results from the Prospective ProMPT trial.
Mandel PC; Huland H; Tiebel A; Haese A; Salomon G; Budäus L; Tilki D; Chun F; Heinzer H; Graefen M; Pantel K; Riethdorf S; Steuber T
Eur Urol Focus; 2021 Jan; 7(1):55-62. PubMed ID: 31178293
[TBL] [Abstract][Full Text] [Related]
13. Castration-resistant prostate cancer without metastasis at presentation may achieve cancer-specific survival in patients who underwent prior radical prostatectomy.
Kodama H; Koie T; Oikawa M; Narita T; Tanaka T; Noro D; Iwamura H; Tobisawa Y; Yoneyama T; Hashimoto Y; Ohyama C
Int Urol Nephrol; 2020 Apr; 52(4):671-679. PubMed ID: 31897875
[TBL] [Abstract][Full Text] [Related]
14. Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men.
Ross AE; Johnson MH; Yousefi K; Davicioni E; Netto GJ; Marchionni L; Fedor HL; Glavaris S; Choeurng V; Buerki C; Erho N; Lam LL; Humphreys EB; Faraj S; Bezerra SM; Han M; Partin AW; Trock BJ; Schaeffer EM
Eur Urol; 2016 Jan; 69(1):157-65. PubMed ID: 26058959
[TBL] [Abstract][Full Text] [Related]
15. Increased Prostate Cancer Glucose Metabolism Detected by
Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
[TBL] [Abstract][Full Text] [Related]
16. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
[TBL] [Abstract][Full Text] [Related]
17. The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients.
Mauermann J; Fradet V; Lacombe L; Dujardin T; Tiguert R; Tetu B; Fradet Y
Eur Urol; 2013 Jul; 64(1):19-25. PubMed ID: 22901983
[TBL] [Abstract][Full Text] [Related]
18. Intermediate PSA half-life after neoadjuvant hormone therapy predicts reduced risk of castration-resistant prostate cancer development after radical prostatectomy.
Kang YJ; Jang WS; Kwon JK; Yoon CY; Lee JY; Ham WS; Choi YD
BMC Cancer; 2017 Nov; 17(1):789. PubMed ID: 29169347
[TBL] [Abstract][Full Text] [Related]
19. Oncologic outcomes at 10 years following robotic radical prostatectomy.
Diaz M; Peabody JO; Kapoor V; Sammon J; Rogers CG; Stricker H; Lane Z; Gupta N; Bhandari M; Menon M
Eur Urol; 2015 Jun; 67(6):1168-1176. PubMed ID: 24996687
[TBL] [Abstract][Full Text] [Related]
20. Systemic interrogation of immune-oncology-related proteins in patients with locally advanced prostate cancer undergoing androgen deprivation and intensity-modulated radiotherapy.
Guldvik IJ; Ramberg H; Kristensen G; Røder A; Mills IG; Lilleby W; Taskén KA
World J Urol; 2024 Feb; 42(1):95. PubMed ID: 38386171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
